Saturday 17 October 2026 Export CPHI’s income statement to Excel — free account

China Pharma Holdings, Inc.

CPHI Healthcare Drug Manufacturers Specialty & Generic

China Pharma Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.1 million, down 8.49% from fiscal 2024. In the quarter to June 2026, revenue fell 7.56%, EPS grew 75.0%, free cash flow fell 113.6% and total debt fell 2.92%, each against the same quarter a year earlier.

0.71 0.02 −2.74%

Follow CPHI

Alert me

Market cap: $31.3M
P/E: 0.0×
Fwd P/E: −1.3×
Dividend yield: —
F-score: 5/9
Altman Z: −2.16
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.45%

Capital & Financial Ratios $m

Market Cap 31.32

Revenue 3.91

Net Income (4.47)

Free Cash Flow (0.14)

Net Debt 1.65

Current Ratio 0.26

Debt/Equity 0.05

P/E ratio 0.00

Fwd P/E (1.27)

P/S ratio 7.35

P/B ratio 0.80

Past 5Y EPS Growth —

This Y EPS Growth —

Next Y EPS Growth —

Next Y revenue growth (15.99%)

Next 5Y EPS Growth 10.00%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 97.86%

10-year low 10-year high

P/B against its own 10 years 64.58%

10-year low 10-year high

EV/Sales against its own 10 years 97.86%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2020	Powerpack
2019	Powerpack
2018	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	1	1	0	0
Receivables	1	0	0	0
Inventory	4	2	2	1
Other	0	0	0	0
	6	3	2	2

	2023	2024	2025	Q'26
Payables	1	0	1	1
ST’ Debt	1	1	2	2
Other	0	0	0	0
	7	5	7	8

Compound Annual Growth %

	10y	5y	3y
Sales	(14.71%)	(17.53%)	(20.03%)
Cash Flow	(26.78%)	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(10.97%)	23.22%	74.36%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	1	1	—	—	—
’25	1	1	1	1	4
’24	1	1	1	1	5
’23	2	1	2	2	7
’22	2	2	2	3	8
’21	2	2	2	3	10
’20	2	4	2	3	11

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	0	0	—	—	—
’25	0	0	0	0	0
’24	(1)	0	0	0	0
’23	(1)	0	1	0	(1)
’22	(1)	0	0	1	0
’21	0	1	0	0	0
’20	0	0	0	0	0

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	0	0	—	—	—
’25	0	0	0	0	0
’24	(1)	0	0	0	(1)
’23	(1)	0	1	0	(1)
’22	(1)	(1)	0	1	(1)
’21	0	1	(1)	0	(1)
’20	(1)	0	0	1	(1)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.04)	(0.04)	—	—	—
’25	(0.24)	(0.16)	(0.17)	(0.18)	(0.74)
’24	(0.70)	(0.90)	(0.60)	(0.50)	(2.70)
’23	(3.00)	(3.00)	(3.00)	0.30	(9.10)
’22	(10.00)	(10.00)	(7.90)	(9.87)	(38.00)
’21	(10.00)	(10.00)	(10.00)	(10.00)	(35.00)
’20	(7.58)	0.15	(10.00)	(15.00)	(35.00)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	60.00	75.00	85.00	105.00	120.00	200.00	45.00	4.00	1.30	1.18	Analyst estimates 2026–2028 Powerpack
	High	175.00	165.00	725.00	290.00	700.00	815.00	265.00	60.00	6.50	3.40
People
People	Employees	385	296	252	242	248	246	244	239	231	221
	Revenue/emp, $m	0.04	0.04	0.05	0.05	0.04	0.04	0.03	0.03	0.02	0.02
Income, $m
Income, $m	Revenue	16	13	12	11	11	10	8	7	5	4
	Gross margin, %	20.67	18.68	16.02	13.57	17.97	3.62	(6.09)	(4.01)	(43.84)	(3.18)
	EBT	(9)	(19)	(11)	(21)	(3)	(3)	(4)	(3)	(5)	(3)
	EBT margin, %	(56.99)	(144.98)	(88.07)	(189.51)	(26.38)	(35.26)	(49.02)	(43.91)	(104.58)	(76.92)
	Net income	(9)	(19)	(11)	(21)	(3)	(3)	(4)	(3)	(5)	(3)
	Depreciation	3	3	3	3	3	3	3	3	3	2
Per share, $
Per share, $	Revenue	178.56	151.52	141.41	125.27	124.62	104.46	77.11	20.72	2.59	0.97
	Earnings	(105.00)	(220.00)	(125.00)	(240.00)	(35.00)	(35.00)	(38.00)	(9.10)	(2.70)	(0.74)
	Cash flow	33.21	9.65	21.58	6.98	(0.49)	(2.71)	(3.90)	(2.07)	(0.23)	0.03
	Capex	(2.22)	(1.57)	(0.59)	(1.56)	(9.95)	(4.75)	(3.82)	(0.03)	(0.17)	(0.03)
	Free cash flow	30.99	8.08	21.00	5.42	(10.43)	(7.45)	(7.72)	(2.10)	(0.40)	0.00
	Book value	675.56	493.94	346.32	105.94	91.79	65.20	40.82	22.03	4.44	5.30
	Shares, m	0	0	0	0	0	0	0	0	2	4
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	0.70	0.56	0.92	0.96	1.81	2.30	0.58	0.29	0.89	1.25
	P/B	0.19	0.17	0.38	1.13	2.45	3.68	1.10	0.27	0.52	0.23
	EV/Sales	1.11	1.05	1.25	1.24	2.19	2.78	1.22	0.43	1.28	1.97
	EV/FCF	22.38	(11.28)	(151.42)	(9.27)	(8.39)	(11.21)	(3.60)	(1.13)	(2.47)	(184.67)
Cash, $m
Cash, $m	Operating cash flow	3	1	2	1	0	0	0	(1)	0	0
	Capex	0	0	0	0	(1)	0	0	0	0	0
	Free cash flow	3	1	2	0	(1)	(1)	(1)	(1)	(1)	0
Balance, $m
Balance, $m	Working capital	7	3	(1)	(4)	(6)	(1)	(7)	(1)	(2)	(5)
	Total debt	10	9	7	4	5	10	2	2	2	2
	Net debt	6	6	4	3	4	5	0	1	2	2
	Shareholders’ equity	59	43	30	9	8	6	4	7	8	23
Returns, %
Returns, %	ROA	(10.49)	(27.84)	(20.41)	(61.24)	(13.23)	(15.53)	(19.65)	(17.98)	(30.21)	(13.89)
	ROIC	(7.81)	(23.58)	(19.06)	(103.64)	(13.17)	(16.79)	(47.32)	(20.46)	(30.16)	(8.31)
	ROE	(13.96)	(37.81)	(29.34)	(104.99)	(33.25)	(48.49)	(77.08)	(52.43)	(62.31)	(20.91)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ZYBT Zhengye Biotechnology Holding Limited	$44.6M	—	—	—	—	−69.31% (below 0%: shrinking)	—	—	Compare
SCYX SCYNEXIS, Inc.	$38.9M	— (loss-making)	— (loss-making)	−8.56% (below 0%: shrinking)	n/m	−98.60% (below 0%: shrinking)	100.00%	(3,308.51%)	Compare
IXHL Incannex Healthcare Inc.	$36.1M	— (loss-making)	— (loss-making)	−92.31% (below 0%: shrinking)	n/m	+327.73% (above 0%: growing)	100.00%	0.00%	Compare
RMTI Rockwell Medical, Inc.	$32.2M	— (loss-making)	— (loss-making)	+10.63% (above 0%: growing)	n/m	−12.92% (below 0%: shrinking)	18.24%	(5.97%)	Compare
CPHI China Pharma Holdings, Inc.	$31.3M	— (loss-making)	— (loss-making)	−7.56% (below 0%: shrinking)	n/m	−113.57% (below 0%: shrinking)	8.82%	(150.99%)
SHPH Shuttle Pharmaceuticals Holdings, Inc.	$26.5M	0.2×	—	—	n/m	+82.01% (above 0%: growing)	0.00%	0.00%	Compare
TXMD TherapeuticsMD, Inc.	$22.3M	— (loss-making)	18.9×	−8.72% (below 0%: shrinking)	−80.00% (below 0%: shrinking)	+104.46% (above 0%: growing)	100.00%	(93.90%)	Compare
AYTU Aytu BioPharma, Inc.	$21.8M	— (loss-making)	— (loss-making)	+6.42% (above 0%: growing)	n/m	+57.72% (above 0%: growing)	64.63%	(4.82%)	Compare
UPC Universe Pharmaceuticals INC	$20.9M	— (loss-making)	4.1×	−23.98% (below 0%: shrinking)	−110.15% (below 0%: shrinking)	−84.99% (below 0%: shrinking)	32.57%	0.00%	Compare
Median of peers	$29.4M	—	—	−8.64%	—	+22.40%	64.63%	(4.82%)

All 86 Drug Manufacturers Specialty & Generic stocks →